½ÃÀ庸°í¼­
»óǰÄÚµå
1519735

Àº â»ó ÇǺ¹Àç ½ÃÀå º¸°í¼­ : À¯Çü, Áúȯ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2024-2032³â)

Silver Wound Dressing Market Report by Type, Disease, End User, and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 135 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Àº â»ó ÇǺ¹Àç ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 9¾ï 7,010¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2032³â±îÁö 13¾ï 8,670¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2024-2032³â 4%ÀÇ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù.

Àº â»ó ÇǺ¹ÀçÀº »óó¿¡ ÀÏÁ¤·®ÀÇ ÀºÀ» ¹æÃâÇÏ¿© Ç×±Õ ¹× »ì±Õ ÀÛ¿ëÀ» ÇÏ´Â ±¹¼Ò »óó Ä¡·á Á¦Ç°À» ¸»ÇÕ´Ï´Ù. À庮Ãþ, ½¡ õ µå·¹½Ì, Æû µå·¹½Ì, ÇÏÀ̵å·ÎÄÝ·ÎÀÌµå µîÀÇ ÇüÅ·Π³Î¸® ÆÇ¸ÅµÇ°í ÀÖ½À´Ï´Ù. Àº µå·¹½Ì Àç·á´Â ¼ö¼ú »óó, È­»ó, ¿åâ, ¿åâ, ÇÏÁö ±Ë¾ç, ´ç´¢º´¼º Á·ºÎ ±Ë¾ç°ú °°Àº ±Þ¼º ¹× ¸¸¼º »óó¿¡¼­ »ïÃâ¾×ÀÌ ÃÖ¼Ò, Áߵ ¶Ç´Â ´Ù·®ÀÇ °æ¿ì 1Â÷ ¶Ç´Â ÀÌÂ÷ µå·¹½Ì Àç·á·Î »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. Àº â»ó ÇǺ¹ÀçÀº ¶ÇÇÑ ¾Ð¹Ú ¶Ç´Â ¼±ÅÃµÈ ±¹¼Ò ¿ä¹ý ¹× º¸Á¶ ¿ä¹ý°ú ÇÔ²² »ç¿ëÇÏ¿© ¹ÚÅ׸®¾Æ ºÎÇϸ¦ ÁÙÀÌ°í »ïÃâ¹°À» ºÀ¼âÇÏ¸ç »óóÀÇ À°¾Æ Á¶Á÷ ¿Ü°üÀ» °³¼± ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÃÖ±Ù Àº â»ó ÇǺ¹ÀçÀº ±¹¼Ò °¨¿° ¹× »ý¹°ÇÐÀû ºÎÇÏ À§ÇèÀÌ ÀÖ´Â ±Þ¼º ¶Ç´Â ¸¸¼º »óó¸¦ Ä¡·áÇϱâ À§ÇØ ÀÇ·á ¾÷°è¿¡¼­ Å« Àα⸦ ¾ò°í ÀÖ½À´Ï´Ù.

Àº â»ó ÇǺ¹Àç Àç·á ½ÃÀå µ¿Çâ :

Àº â»ó ÇǺ¹ÀçÀº °¨¿°À» ¿¹¹æÇÏ°í ¿ÏÈ­ÇÏ´Â µ¥ µµ¿òÀÌ µÇ¸ç, ±¤¹üÀ§ÇÑ Ç×±Õ È°¼ºÀ» Á¦°øÇÏ°í »óó³» ¸ÞÅ»·ÎÇÁ·ÎÅ×¾ÆÁ¦¸¦ º¯È­½Ãŵ´Ï´Ù. ±× °á°ú, Àº â»ó ÇǺ¹ÀçÀº ±âÁ¸ÀÇ »óó Ä¡·á ¹× »óó ºÀÇÕ Á¦Ç°À» ´ëüÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ ¸¸¼º »óó¿Í È­»ó Áõ°¡, °í±Þ »óó Ä¡·á¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Àº â»ó ÇǺ¹Àç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¾Ï, ´ç´¢º´, ½ÉÇ÷°ü Áúȯ(CVD) µî ¸¸¼ºÁúȯÀÇ À¯º´·üÀÌ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² ¼ö¼úÀ» ¹Þ´Â ȯÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¼ö¼ú ºÎÀ§ °¨¿°À» ¿¹¹æÇÏ°í »óó Ä¡À¯¸¦ ÃËÁøÇÏ´Â Àº â»ó ÇǺ¹ÀçÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀϺΠÁÖ¿ä ¾÷üµéÀº Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇÏ°í °æÀï·ÂÀ» È®º¸Çϱâ À§ÇØ »õ·Ó°í Çõ½ÅÀûÀÎ Àº â»ó ÇǺ¹ÀçÀ» Ãâ½ÃÇϱâ À§ÇØ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ÀçÅÃÄ¡·áÀÇ ºÎ»ó, ±³Åë»ç°í Áõ°¡, °í·ÉÈ­, ÀÇ·á ÀÎÇÁ¶ó °³¼±, ±â¼ú ¹ßÀü, ±¤¹üÀ§ÇÑ Á¶»ç °³¹ß Ȱµ¿°ú °°Àº ´Ù¸¥ ¿äÀε鵵 ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

  • ¼¼°è Àº â»ó ÇǺ¹Àç Àç·á ½ÃÀå ±Ô¸ð´Â?
  • 2024-2032³â ¼¼°è Àº â»ó ÇǺ¹Àç ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀº?
  • ¼¼°è Àº â»ó ÇǺ¹Àç ½ÃÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?
  • COVID-19°¡ Àü ¼¼°è Àº â»ó ÇǺ¹Àç Àç·á ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
  • ¼¼°è Àº â»ó ÇǺ¹ÀçÀç ½ÃÀåÀÇ Áúº´º° ½ÃÀå ÇöȲÀº?
  • ¼¼°è Àº â»ó ÇǺ¹Àç Àç·á ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀº?
  • ¼¼°è Àº â»ó ÇǺ¹Àç Àç·á ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • º¸ÅÒ¾÷ Á¢±Ù
    • Åé´Ù¿î Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ¼­·Ð

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ÀºÃ¢»ó ÇǺ¹Àç ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : À¯Çüº°

  • ÇÏÀ̵å·Î ¼¶À¯ Àº µå·¹½Ì
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ³ª³ë °áÁ¤ Àº µå·¹½Ì
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Àºµµ±Ý ³ªÀÏ·Ð ¼¶À¯ µå·¹½Ì
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Áú»ê Àº µå·¹½Ì
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¾Ë±ä»ê Àº µå·¹½Ì
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦7Àå ½ÃÀå ³»¿ª : Áúȯº°

  • ±Ë¾ç
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • È­»ó
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Àý»ó°ú ¿­»ó
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦8Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°

  • ÀÔ¿ø ½Ã¼³
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¿Ü·¡ ½Ã¼³
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦9Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ³»¿ª : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦10Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ¹ÙÀ̾îÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀïÀÇ Á¤µµ
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ÀÇ °³¿ä
    • 3M Company
    • Advanced Medical Solutions Group plc
    • B. Braun Melsungen AG
    • Cardinal Health Inc.
    • Coloplast A/S
    • ConvaTec Group plc
    • Ferris Mfg. Corp.
    • Hollister Incorporated
    • Integra LifeSciences
    • Medline Industries LP
    • Molnlycke Health Care AB
    • Smith & Nephew plc
KSA 24.07.30

The global silver wound dressing market size reached US$ 970.1 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,386.7 Million by 2032, exhibiting a growth rate (CAGR) of 4% during 2024-2032.

Silver wound dressings refer to topical wound care products that release a steady amount of silver to the wound to provide antimicrobial and antibacterial action. They are widely available in the form of barrier layers, charcoal cloth dressings, foam dressings, and hydrocolloids. Silver dressings can be used as primary or secondary dressings to manage minimal, moderate, or heavy exudate in acute and chronic wounds, such as surgical wounds, burns, pressure ulcers, leg ulcers, and diabetic foot ulcers. They can also be utilized under compression or with select topical and adjunctive therapies to reduce the bacterial load, contain exudate, and improve the appearance of the wound's granulation tissue. In recent years, silver wound dressings have gained immense popularity in the healthcare industry to treat acute or chronic wounds with or at risk of local infection or bioburden.

Silver Wound Dressing Market Trends:

Silver wound dressings help prevent and reduce infections, provide a wide range of antimicrobial activity, and alter metalloproteinases within wounds. As a result, silver wound dressings are rapidly replacing traditional wound care and closure products, which represents the primary factor driving the market growth. Besides this, the rising incidences of chronic wounds and burns and the growing awareness regarding advanced wound care treatment are catalyzing the demand for silver wound dressings. Additionally, there has been a significant increase in the prevalence of chronic conditions, such as cancer, diabetes, and cardiovascular diseases (CVDs). Along with this, the increasing number of patients undergoing surgeries is encouraging the adoption of silver wound dressings to prevent surgical site infections and promote faster wound healing. Furthermore, several key players are making heavy investments to launch new and innovative silver wound dressing variants to expand their product portfolio and gain a competitive edge. Other factors, including the emerging trend of home healthcare, rising cases of road accidents, aging population, improving healthcare infrastructure, technological advancements, and extensive research and development (R&D) activities, are also providing a positive thrust to the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global silver wound dressing market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, disease and end user.

Breakup by Type:

Hydrofiber Silver Dressings

Nanocrystalline Silver Dressing

Silver Plated Nylon Fiber Dressing

Silver Nitrate Dressing

Silver Alginate Dressing

Others

Breakup by Disease:

Ulcers

Burns

Cuts and Lacerations

Others

Breakup by End User:

Inpatient Facilities

Outpatient Facilities

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Advanced Medical Solutions Group plc, B. Braun Melsungen AG, Cardinal Health Inc., Coloplast A/S, ConvaTec Group plc, Ferris Mfg. Corp., Hollister Incorporated, Integra LifeSciences, Medline Industries LP, Molnlycke Health Care AB and Smith & Nephew plc.

Key Questions Answered in This Report

  • 1. How big is the global silver wound dressing market?
  • 2. What is the expected growth rate of the global silver wound dressing market during 2024-2032?
  • 3. What are the key factors driving the global silver wound dressing market?
  • 4. What has been the impact of COVID-19 on the global silver wound dressing market?
  • 5. What is the breakup of the global silver wound dressing market based on the disease?
  • 6. What is the breakup of the global silver wound dressing market based on the end user?
  • 7. What are the key regions in the global silver wound dressing market?
  • 8. Who are the key players/companies in the global silver wound dressing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Silver Wound Dressing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Hydrofiber Silver Dressings
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Nanocrystalline Silver Dressing
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Silver Plated Nylon Fiber Dressing
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Silver Nitrate Dressing
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Silver Alginate Dressing
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Disease

  • 7.1 Ulcers
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Burns
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Cuts and Lacerations
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Inpatient Facilities
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Outpatient Facilities
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 3M Company
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Advanced Medical Solutions Group plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 B. Braun Melsungen AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Cardinal Health Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Coloplast A/S
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 ConvaTec Group plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Ferris Mfg. Corp.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Hollister Incorporated
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 SWOT Analysis
    • 14.3.9 Integra LifeSciences
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Medline Industries LP
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 Molnlycke Health Care AB
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 SWOT Analysis
    • 14.3.12 Smith & Nephew plc
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦